JPWO2019191633A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191633A5 JPWO2019191633A5 JP2020551860A JP2020551860A JPWO2019191633A5 JP WO2019191633 A5 JPWO2019191633 A5 JP WO2019191633A5 JP 2020551860 A JP2020551860 A JP 2020551860A JP 2020551860 A JP2020551860 A JP 2020551860A JP WO2019191633 A5 JPWO2019191633 A5 JP WO2019191633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- lysate
- component
- pseudomonas aeruginosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 84
- 229920001184 polypeptide Polymers 0.000 claims 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 239000006166 lysate Substances 0.000 claims 30
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 claims 25
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 24
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 22
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 22
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 18
- 230000035772 mutation Effects 0.000 claims 18
- 102000040430 polynucleotide Human genes 0.000 claims 18
- 108091033319 polynucleotide Proteins 0.000 claims 18
- 239000002157 polynucleotide Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 14
- 230000002101 lytic effect Effects 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 10
- 241000894006 Bacteria Species 0.000 claims 9
- 230000001580 bacterial effect Effects 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 230000000087 stabilizing effect Effects 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 101100280481 Caenorhabditis elegans lbp-2 gene Proteins 0.000 claims 5
- 241001510512 Chlamydia phage 2 Species 0.000 claims 5
- 241000839426 Chlamydia virus Chp1 Species 0.000 claims 5
- 101150071546 Chp1 gene Proteins 0.000 claims 5
- 101150009410 Chp2 gene Proteins 0.000 claims 5
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims 5
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims 5
- 101100533947 Mus musculus Serpina3k gene Proteins 0.000 claims 5
- 101100257418 Mus musculus Serpina3n gene Proteins 0.000 claims 5
- 101150009018 SPI-1 gene Proteins 0.000 claims 5
- -1 aminoglycoside Chemical compound 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- VNUQOJUAIRBYQO-PPAUOFQQSA-N esculentin Chemical group O([C@H]1[C@@H](OC)C[C@@H](O[C@@H]1C)O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2CC3=CC[C@@]4(O)[C@@]5(O)CC[C@](O)([C@@]5(C)[C@H](O)[C@@H](O)C4[C@@]3(C)CC2)C(C)=O)C[C@H]1OC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](OC)[C@H]1O VNUQOJUAIRBYQO-PPAUOFQQSA-N 0.000 claims 5
- 241000894007 species Species 0.000 claims 5
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 125000003345 AMP group Chemical group 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 2
- 241000588914 Enterobacter Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000588748 Klebsiella Species 0.000 claims 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- 229960004682 cefoperazone Drugs 0.000 claims 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650235P | 2018-03-29 | 2018-03-29 | |
| US62/650,235 | 2018-03-29 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| US201862722793P | 2018-08-24 | 2018-08-24 | |
| US62/722,793 | 2018-08-24 | ||
| PCT/US2019/024912 WO2019191633A2 (en) | 2018-03-29 | 2019-03-29 | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519083A JP2021519083A (ja) | 2021-08-10 |
| JP2021519083A5 JP2021519083A5 (https=) | 2022-04-04 |
| JPWO2019191633A5 true JPWO2019191633A5 (https=) | 2022-04-04 |
Family
ID=68060804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551860A Pending JP2021519083A (ja) | 2018-03-29 | 2019-03-29 | 溶解素−抗微生物ペプチド（ａｍｐ）ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773140B2 (https=) |
| EP (1) | EP3775192A4 (https=) |
| JP (1) | JP2021519083A (https=) |
| KR (1) | KR20200136980A (https=) |
| CN (1) | CN112368376A (https=) |
| AU (1) | AU2019245369A1 (https=) |
| BR (1) | BR112020019484A2 (https=) |
| CA (1) | CA3095484A1 (https=) |
| IL (1) | IL277119B2 (https=) |
| MX (1) | MX2020010075A (https=) |
| WO (1) | WO2019191633A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200783A2 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210330738A1 (en) * | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| CN114040773A (zh) * | 2019-04-05 | 2022-02-11 | 康特拉费克特公司 | 在存在人血清的情况下对铜绿假单胞菌具有杀菌活性的溶素及其衍生物 |
| KR20220029746A (ko) * | 2019-07-05 | 2022-03-08 | 콘트라펙트 코포레이션 | 항미생물성 박테리오파지 유도된 폴리펩타이드 및 이의 그람 음성 및 항산성 세균에 대한 사용 |
| EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corporation | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
| WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
| KR20230162045A (ko) * | 2021-03-26 | 2023-11-28 | 콘트라펙트 코포레이션 | 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물 |
| WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
| FR3149209B1 (fr) * | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| FR3149202B1 (fr) * | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| EP4719330A1 (en) * | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149203B1 (fr) * | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| WO2024256710A2 (en) | 2023-06-15 | 2024-12-19 | Aurobac Therapeutics Sas | Engineered lysin polypeptide constructs active against gram-negative bacteria |
| WO2025054593A2 (en) * | 2023-09-07 | 2025-03-13 | The Trustees Of The University Of Pennsylvania | Molecular de-extinction of antibiotics enabled by deep learning |
| CN120924524B (zh) * | 2025-10-14 | 2026-01-06 | 中国海洋大学 | 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0517477A (pt) | 2004-11-12 | 2008-10-07 | Novozymes As | polipeptìdeo, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir um polipeptìdeo, um polinucleotìdeo, e uma proteìna, planta, parte de planta ou célula vegetal transgênicas, método para matar ou inibir o crescimento de células microbianas, e, uso de um polipeptìdeo antimicrobiano |
| SG176783A1 (en) | 2009-06-16 | 2012-01-30 | Univ Tokai | Anti-gram-negative bacteria agent |
| PL2445515T3 (pl) * | 2009-06-26 | 2016-10-31 | Środki przeciwdrobnoustrojowe | |
| AU2010264659B2 (en) * | 2009-06-26 | 2016-08-04 | Lysando Aktiengesellschaft | Antimicrobial agents |
| KR20120059576A (ko) | 2009-08-24 | 2012-06-08 | 뤼산도 홀딩 아게 | 신규한 엔도리신 ＯＢＰｇｐＬＹＳ |
| EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| EP2699689A4 (en) | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| EP2702070B1 (en) | 2011-04-27 | 2015-09-30 | Lysando AG | New antimicrobial agents |
| WO2012159774A1 (en) | 2011-05-26 | 2012-11-29 | Dsm Ip Assets B.V. | Novel listeria bacteriophage p825n and uses thereof |
| US8790639B2 (en) | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
| KR101391332B1 (ko) | 2012-05-18 | 2014-05-07 | 연세대학교 산학협력단 | 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지 |
| US9388400B2 (en) * | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
| CN102861324A (zh) * | 2012-10-17 | 2013-01-09 | 重庆市第三人民医院 | 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂 |
| WO2015200783A2 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| EP4115897A1 (en) | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR102000120B1 (ko) | 2017-01-26 | 2019-07-15 | 주식회사 코미팜 | 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물 |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| US20210330738A1 (en) | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 WO PCT/US2019/024912 patent/WO2019191633A2/en not_active Ceased
- 2019-03-29 BR BR112020019484-0A patent/BR112020019484A2/pt unknown
- 2019-03-29 CN CN201980036007.XA patent/CN112368376A/zh active Pending
- 2019-03-29 IL IL277119A patent/IL277119B2/en unknown
- 2019-03-29 KR KR1020207031049A patent/KR20200136980A/ko active Pending
- 2019-03-29 JP JP2020551860A patent/JP2021519083A/ja active Pending
- 2019-03-29 EP EP19776817.9A patent/EP3775192A4/en not_active Withdrawn
- 2019-03-29 AU AU2019245369A patent/AU2019245369A1/en not_active Abandoned
- 2019-03-29 CA CA3095484A patent/CA3095484A1/en active Pending
- 2019-03-29 MX MX2020010075A patent/MX2020010075A/es unknown
- 2019-03-29 US US17/041,691 patent/US11773140B2/en active Active
-
2023
- 2023-08-18 US US18/452,038 patent/US20240018192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519083A5 (https=) | ||
| JPWO2019191633A5 (https=) | ||
| IL277119B2 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| JP2024010053A5 (https=) | ||
| JP2021506769A5 (https=) | ||
| JP2021533728A5 (https=) | ||
| RU2018107245A (ru) | Полипептиды лизина, активные против грамотрицательных бактерий | |
| US20180271952A1 (en) | Combination of Bactericidal Agent With a Lysosomotropic Alkalinising Agent for the Treatment of a Bacterial Infection | |
| Wang et al. | The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region | |
| JP2024010053A (ja) | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 | |
| IL313959A (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| JP7288851B2 (ja) | エンテロコッカス属細菌に対する新規抗微生物剤 | |
| JP2021519311A5 (https=) | ||
| CN112166190A (zh) | 新抗微生物蛋白 | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| CN110036105A (zh) | 经修饰的肽 | |
| Borysowski et al. | Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives | |
| JPWO2020046747A5 (https=) | ||
| JPWO2021180892A5 (https=) | ||
| JPWO2019191598A5 (https=) | ||
| CA3136126A1 (en) | Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum | |
| JPWO2020206327A5 (https=) | ||
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| JPWO2021097192A5 (https=) | ||
| RU2022126282A (ru) | Новый рекомбинантный лизин и его применение в лечении грамотрицательных бактериальных инфекций |